Literature DB >> 11165224

Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum.

B H Westerink1, Y Kawahara, P De Boer, C Geels, J B De Vries, H V Wikström, A Van Kalkeren, B Van Vliet, C G Kruse, S K Long.   

Abstract

Dose-effect curves were established for the effects of the antipsychotic drugs haloperidol, clozapine, olanzapine, risperidone and ziprasidone on extracellular levels of dopamine and noradrenaline in the medial prefrontal cortex, and of dopamine in the striatum. Haloperidol was more effective in stimulating the release of dopamine in the striatum, whereas clozapine was much more effective in the medial prefrontal cortex. The efficacy of risperidone, olanzapine and ziprasidone did not differ for the two brain areas. The benzamides sulpiride and raclopride increased dopamine release in the striatum but did not affect the release of dopamine and noradrenaline in the medial prefrontal cortex. In the presence of dopamine/noradrenaline reuptake inhibitors, the benzamides strongly increased the release of dopamine-but not of noradrenaline-in the medial prefrontal cortex. The 5-HT(2) receptor antagonist R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol (MDL100,907) (800 nmol/kg) and the dopamine D(2) receptor antagonist raclopride (2 micromol/kg) displayed a clear synergism in increasing the release of dopamine in the medial prefrontal cortex. No such synergism was seen in the case of noradrenaline. Co-administration of the 5-HT(2) receptor agonist (+/-)-2,5-dimethoxy-4-iodoamphetamine HCl (DOI) (850 nmol/kg) with clozapine (10 micromol/kg) or haloperidol (800 nmol/kg) blocked the increase in dopamine as well as noradrenaline in the medial prefrontal cortex. It is concluded that typical and non-benzamide atypical antipsychotics increase extracellular dopamine in the medial prefrontal cortex via a synergistic interaction by blocking 5-HT(2) as well as dopamine D(2) receptors. The increase in extracellular noradrenaline in the medial prefrontal cortex that was observed after administration of antipsychotics is explained by inhibition of 5-HT(2) receptors and not dopamine D(2) receptors. Finally, the significance of the classification of antipsychotic drugs based on their selective action on the release of dopamine and noradrenaline in the medial prefrontal cortex is discussed. In particular, the position of the benzamides is discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165224     DOI: 10.1016/s0014-2999(00)00935-3

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  28 in total

1.  The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Authors:  Eleni T Tzavara; Richard J Davis; Kenneth W Perry; Xia Li; Craig Salhoff; Frank P Bymaster; Jeffrey M Witkin; George G Nomikos
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

2.  Impaired D2 dopamine receptor function in mice lacking type 5 adenylyl cyclase.

Authors:  Ko-Woon Lee; Jang-Hee Hong; In Young Choi; Yongzhe Che; Ja-Kyeong Lee; Sung-Don Yang; Chang-Woo Song; Ho Sung Kang; Jae-Heun Lee; Jai Sung Noh; Hee-Sup Shin; Pyung-Lim Han
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

Review 3.  Antipsychotic and antidepressive effects of second generation antipsychotics: two different pharmacological mechanisms?

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

4.  Effects of amisulpride on human resting cerebral perfusion.

Authors:  Roberto Viviani; Heiko Graf; Maike Wiegers; Birgit Abler
Journal:  Psychopharmacology (Berl)       Date:  2013-04-13       Impact factor: 4.530

Review 5.  Pharmacologic mechanisms of serotonergic regulation of dopamine neurotransmission.

Authors:  K D Alex; E A Pehek
Journal:  Pharmacol Ther       Date:  2006-10-17       Impact factor: 12.310

6.  Differential impact of pavlovian drug conditioned stimuli on in vivo dopamine transmission in the rat accumbens shell and core and in the prefrontal cortex.

Authors:  Valentina Bassareo; Maria Antonietta De Luca; Gaetano Di Chiara
Journal:  Psychopharmacology (Berl)       Date:  2006-10-28       Impact factor: 4.530

7.  Preclinical investigations into the antipsychotic potential of the novel histamine H3 receptor antagonist GSK207040.

Authors:  Eric Southam; Jackie Cilia; Jane E Gartlon; Marie L Woolley; Laurent P Lacroix; Carol A Jennings; Jane E Cluderay; Charlie Reavill; Claire Rourke; David M Wilson; Lee A Dawson; Andrew D Medhurst; Declan N C Jones
Journal:  Psychopharmacology (Berl)       Date:  2008-09-03       Impact factor: 4.530

8.  Methylphenidate boosts choices of mental labor over leisure depending on striatal dopamine synthesis capacity.

Authors:  Lieke Hofmans; Danae Papadopetraki; Ruben van den Bosch; Jessica I Määttä; Monja I Froböse; Bram B Zandbelt; Andrew Westbrook; Robbert-Jan Verkes; Roshan Cools
Journal:  Neuropsychopharmacology       Date:  2020-09-12       Impact factor: 7.853

9.  Presynaptic regulation of extracellular dopamine levels in the medial prefrontal cortex and striatum during tyrosine depletion.

Authors:  Zachary Brodnik; Manda Double; George E Jaskiw
Journal:  Psychopharmacology (Berl)       Date:  2013-02-01       Impact factor: 4.530

Review 10.  Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia.

Authors:  Yael Chertkow; Orly Weinreb; Moussa B H Youdim; Henry Silver
Journal:  J Neural Transm (Vienna)       Date:  2009-07-04       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.